Frontlight ResearchEarly access
Not yet recruitingNo phase
First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression
Key facts
- Who runs it
- hemotune AG
- Where
- Switzerland2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 16 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Hemosystem REBOOT
- Record updated
- 14 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 18 years
- Written informed consent according to national requirements
- Hospitalized in ICU or IMC at randomization
- Expected length of intensive care unit stay (from randomization) >48 hours
- Suspected or confirmed bacterial sepsis
- Septic shock diagnosis at any time during ICU/IMC stay according to Sepsis - 3 criteria definition:; an infection (suspected or confirmed); persisting hypotension requiring any dose of vasopressors (norepinephrine, vasopressin) to maintain a systemic mean blood pressure > 65 mmHg despite adequate fluid resuscitation (minimum of 30 ml/kg crystalloids); elevated lactate ≥ 2.0 mmol/L with suspected hypoperfusion
- Persistent immunosuppression defined as mHLA-DR expression levels < 5600 Ab/cell (Cyto-Chex tubes) in at least two consecutive measurements 20-72 hours apart
Who cannot take part
- Patients post solid-organ transplantation
- Patient with preexisting known severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS)
- Known active malignancy (i.e. patients under active anti-malignant treatment)
- Known history of bleeding disorders or severe coagulopathies (e.g., Hemophilia A, Hemophilia B, Idiopathic Thrombocytopenic Purpura, Von Willebrand Disease types I, II, and III)
- Current ongoing chronic treatment using immunosuppressive biologicals or active lymphocyte therapy (e.g. endoxan, rituximab) or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute treatment using a maximum dose of hydrocortisone of 200 mg/day for sepsis is allowed
- Contraindication to use the HemoSystem:; Sensitivity / allergy to HemoSystem components; Body weight < 50 kg; Platelets count < 20,000/µL; History of heparin-induced thrombocytopenia
- Females who are known to be pregnant or known to be breastfeeding (b-HCG testing performed in female patients aged < 55 years),
- Active or planned extracorporeal membrane oxygenation treatment
- Active or planned other extracorporeal blood purification treatments with systems like CytoSorb®, ToraymyxinTM, Gambro Adsorba, etc
- Acute severe burn injury > 20% of the body surface area
- Moribund patient with life expectancy < 48h
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.
The 2 groups in the trial
- Treatment armTreatment being tested
The REBOOT Hemosystem will be tested in the treatment arm for a maximum of 5 treatments, the treatment will be applied in addition to standard of care alone.
Treatment: Hemosystem REBOOT
- Standard of careNo study treatment, for comparison
Best standard of care will be applied to these patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)
- Record updated
- 14 March 2025